Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals
November 28, 2012 at 09:54 AM EST
In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX ). Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of
